Cue biopharma announces $30 million private investment in public equity (pipe) financing

Boston, nov. 14, 2022 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific t cells directly within the patient's body, announced today that it has entered into securities purchase agreements with certain accredited investors for a $30 million private investment in public equity (pipe) financing.
CUE Ratings Summary
CUE Quant Ranking